Literature DB >> 22970042

The binding characteristics of a cyclic nonapeptide, c(CGRRAGGSC), in LNCaP human prostate cancer cells.

Chen Gu1, Lu Liu, Yujie He, Jianwei Jiang, Zexuan Yang, Qinghua Wu.   

Abstract

Previous studies have demonstrated that interleukin-11 (IL-11) and the IL-11 receptor (IL-11R) are associated with the regulation of tumor progression and may play a significant role in bone metastases. The nonapeptide structure c(CGRRAGGSC) is a phage display-selected IL-11 mimic, which binds to IL-11R. The aim of this study is to investigate the binding characteristics of a cyclic nonapeptide c(CGRRAGGSC) in LNCaP human prostate cancer cells. To investigate its binding and uptake effects, c(CGRRAGGSC) was labeled with a fluorescent dye, LSS670. The binding location of LSS670 cyclic nonapeptide in LNCaP cells was investigated by fluorescence microscopy. Flow cytometry was used to detect the fluorescence of LSS670-c(CGRRAGGSC) in LNCaP cells. The binding of LSS670-c(CGRRAGGSC) in LNCaP cells was inhibited by unlabeled cyclic nonapeptide, depending on the varying density of c(CGRRAGGSC) and different time points. The molecular probe bound to the LNCaP cell membrane and cytoplasm through fluorescence tracing. In the saturation experiments performed in vitro, the K(d) value was 3.2±0.02 nM and the B(max) value was 754±34 fmol/mg.pro. The 50% inhibiting concentration (IC(50)) was 6.31±0.12 nmol/l and the K(i) value was 2.11±0.14 nmol/l in competitive inhibition experiments. Our results suggest that c(CGRRAGGSC) is able to specifically bind to LNCaP cells through a receptor-mediated pathway.

Entities:  

Year:  2012        PMID: 22970042      PMCID: PMC3439175          DOI: 10.3892/ol.2012.769

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  19 in total

1.  Identification of the domain in the human interleukin-11 receptor that mediates ligand binding.

Authors:  K Schleinkofer; A Dingley; I Tacken; M Federwisch; G Müller-Newen; P C Heinrich; P Vusio; Y Jacques; J Grötzinger
Journal:  J Mol Biol       Date:  2001-02-16       Impact factor: 5.469

2.  Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe.

Authors:  Chun Li; Wei Wang; Qingping Wu; Shi Ke; Jessica Houston; Eva Sevick-Muraca; Liang Dong; Diana Chow; Chusilp Charnsangavej; Juri G Gelovani
Journal:  Nucl Med Biol       Date:  2006-04       Impact factor: 2.408

Review 3.  Multistate analysis of skeletal events in patients with bone metastases.

Authors:  Richard J Cook; Pierre Major
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

Review 4.  Testosterone and prostate cancer: an historical perspective on a modern myth.

Authors:  Abraham Morgentaler
Journal:  Eur Urol       Date:  2006-07-27       Impact factor: 20.096

5.  Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway.

Authors:  Yibin Kang; Wei He; Shaun Tulley; Gaorav P Gupta; Inna Serganova; Chang-Rung Chen; Katia Manova-Todorova; Ronald Blasberg; William L Gerald; Joan Massagué
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

6.  Expression of interleukin-11 (IL-11) and IL-11 receptor alpha in human gastric carcinoma and IL-11 upregulates the invasive activity of human gastric carcinoma cells.

Authors:  Toshiyuki Nakayama; Ayumi Yoshizaki; Seiya Izumida; Tomoyuki Suehiro; Shiro Miura; Takashi Uemura; Yuichi Yakata; Kazuko Shichijo; Shunichi Yamashita; Ichiro Sekin
Journal:  Int J Oncol       Date:  2007-04       Impact factor: 5.650

7.  A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain.

Authors:  Wei Wang; Shi Ke; Sunkuk Kwon; Sasidhar Yallampalli; Arlin G Cameron; Kristen E Adams; Michel E Mawad; Eva M Sevick-Muraca
Journal:  Bioconjug Chem       Date:  2007-02-22       Impact factor: 4.774

8.  STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice.

Authors:  Matthias Ernst; Meri Najdovska; Dianne Grail; Therese Lundgren-May; Michael Buchert; Hazel Tye; Vance B Matthews; Jane Armes; Prithi S Bhathal; Norman R Hughes; Eric G Marcusson; James G Karras; Songqing Na; Jonathon D Sedgwick; Paul J Hertzog; Brendan J Jenkins
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

9.  Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer.

Authors:  Amado J Zurita; Patricia Troncoso; Marina Cardó-Vila; Christopher J Logothetis; Renata Pasqualini; Wadih Arap
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

10.  The human IL-11 receptor requires gp130 for signalling: demonstration by molecular cloning of the receptor.

Authors:  H H Nandurkar; D J Hilton; P Nathan; T Willson; N Nicola; C G Begley
Journal:  Oncogene       Date:  1996-02-01       Impact factor: 9.867

View more
  2 in total

Review 1.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

2.  Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study.

Authors:  Renata Pasqualini; Randall E Millikan; Dawn R Christianson; Marina Cardó-Vila; Wouter H P Driessen; Ricardo J Giordano; Amin Hajitou; Anh G Hoang; Sijin Wen; Kirstin F Barnhart; Wallace B Baze; Valerie D Marcott; David H Hawke; Kim-Anh Do; Nora M Navone; Eleni Efstathiou; Patricia Troncoso; Roy R Lobb; Christopher J Logothetis; Wadih Arap
Journal:  Cancer       Date:  2015-04-01       Impact factor: 6.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.